Eribulin mesylate use as third-line therapy in patients with metastatic breast cancer (VESPRY): a prospective, multicentre, observational study

被引：9

作者：

Adamo, Vincenzo ^{[1
,2
,3
,4
,5
]}

Ricciardi, Giuseppina Rosaria Rita ^{[1
,2
]}

Giuffrida, Dario ^{[6
]}

Scandurra, Giuseppa ^{[7
]}

Russo, Antonio ^{[8
]}

Blasi, Livio ^{[9
]}

Spadaro, Pietro ^{[10
]}

Iacono, Carmelo ^{[11
]}

Soto Parra, Hector J. ^{[12
]}

Savarino, Antonino ^{[13
]}

Ferrau, Francesco ^{[14
]}

Zerilli, Filippo ^{[15
]}

Verderame, Francesco ^{[16
]}

Butera, Alfredo ^{[17
]}

Santangelo, Carlo ^{[18
]}

Franchina, Veronica ^{[1
,2
]}

Caruso, Michele ^{[19
]}

机构：

[1] Univ Messina, Med Oncol Unit AO Papardo, Messina, Italy

[2] Univ Messina, Dept Human Pathol, Messina, Italy

[3] Univ Messina, Med Oncol, Messina, Italy

[4] Papardo Hosp, Oncol Hematol Dept, I-98158 Messina, Italy

[5] Papardo Hosp, Med Oncol Unit, I-98158 Messina, Italy

[6] Mediterranean Inst Oncol, Dept Med Oncol, Viagrande, CT, Italy

[7] Osped Emergenze Cannizzaro, Oncol Med, Catania, Italy

[8] Univ Palermo, Sect Med Oncol, Dept Surg Oncol & Oral Sci, Palermo, Italy

[9] ARNAS Civ, UOC Oncol Med, Piazza Nicola Leotta, Palermo, Italy

[10] Casa Cura Villa Salus, UO Oncol & Ematol, Messina, Italy

[11] Osped Maria Paterno Arezzo, Dept Med Oncol, Ragusa, Italy

[12] Univ Hosp Policlin Vittorio Emanuele, Dept Med Oncol, Catania, Italy

[13] Osped Barone Lombardo Canicatti, Unita Operat Oncol, Canicatti, AG, Italy

[14] Osped S Vincenzo, Dept Med Oncol, Taormina, ME, Italy

[15] San Antonio Abate Hosp, Med Oncol, Trapani, Italy

[16] AO Osped Riuniti Villa Sofia Cervello, Palermo, Italy

[17] Hosp Agrigento, Med Oncol, Agrigento, Italy

[18] PO Umberto I, Contrada Ferrante, Enna, Italy

[19] Humanitas Ctr Catanese Oncol, Catania, Italy

来源：

THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY | 2019年 / 11卷

关键词：

eribulin; metastatic breast cancer; multicentre; prospective; real world; third line; ANTHRACYCLINE; EFFICACY; WOMEN; TAXANE; SITE;

D O I：

10.1177/1758835919895755

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Background: In real-world practice, eribulin mesylate provides significant survival benefit, with a manageable safety profile in heavily pretreated patients with metastatic breast cancer (MBC). Methods: In this prospective, open-label, multicentre, observational study we evaluated the effectiveness and tolerability of eribulin as third-line treatment in a homogeneous population. The primary endpoints were the safety profile and response in metastatic sites; secondary endpoints included the response in different subtypes, overall response rate (ORR), progression-free survival (PFS) and overall survival (OS). Results: From 2013 to 2016, 118 women were treated in 21 Sicilian institutions; the median age was 58 years (range 29-79), with 69% of patients under 65. The median cycles of eribulin were 5.5 (range 1-26). The most common adverse event was neutropenia (9.3%, 3 cases of grade 3, 4 of grade 4); only 1 case of QT prolongation was reported. Eribulin was effective in controlling metastatic disease in all sites, and it achieved the highest ORR in brain (16%) and liver (14.9%). Median OS was 31.8 months (95% CI 27.9-34.4) and median PFS 5.5 months (95% CI 4.2-6.6). PFS was 5.2 months (95% CI 2.8-8.4) in patients with triple-negative subtype. Median PFS was longer in patients over 65 years (6.1 months, 95% CI 4.4-8.3). In patients who had visceral metastases PFS was 5.5 months (95% CI 95% 3.5-6.6) and OS 33.9 months (95% CI 29.8-40.8). Conclusions: Eribulin as third-line treatment shows an acceptable safety profile and a substantial antitumour activity in the treatment of MBC, even in elderly patients and in those with visceral disease.

引用

页数：7

共 20 条

[1] Eribulin monotherapy versus treatment of physician's choice in patients with metastatic breast cancer (EMBRACE): a phase 3 open-label randomised study [J].